Tremeau Expands Pipeline with Novel Non-Opioid Compound for the Treatment of Acute Pain

CONCORD, Mass.–(BUSINESS WIRE)–Tremeau Pharmaceuticals today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/240,446. Once issued, the patent will provide composition of matter patent protection for Tremeau’s novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041. Etoricoxib is a highly selective cyclooxygenase-2 (COX-2) non-steroidal anti-inflammatory drug (NSAID) with
Click here to view original post